Empagliflozin suppresses inflammation and protects against acute septic renal injury
ConclusionOverall, the findings of this study suggest that empagliflozin could be repurposed to reduce morbidity and mortality in patients with acute septic renal injury.Trial registrationNot applicable.
Source: Inflammopharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Empagliflozin | Intensive Care | Jardiance | Septic Shock | SGLT2 Inhibitors | Sodium | Study | Urology & Nephrology